In turn, primary care experts called for a PET scan, CT scan and biopsy. Results then showed he had a “very aggressive” form ...

"Full House" star Dave Coulier, 65, has been diagnosed with stage 3 non-Hodgkin lymphoma, the actor revealed in an exclusive ...

Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...

Recent news reveals Full House star Dave Coulier is battling stage 3 lymphoma, drawing attention and concern from fans ...

"Full House" actor Dave Coulier who played Joey Gladstone reveals he has Stage 3 non-Hodgkin lymphoma. He's undergoing ...

Dave Coulier was shocked to learn he has stage 3 non-Hodgkin lymphoma. He opens up to PEOPLE exclusively about his diagnosis and how he has been leaning on family and humor through his cancer journey.

Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.

The actor said the blood cancer is "very treatable" and expects a "total remission." Full House Star Dave Coulier Diagnosed ...

French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma (B-NHL). | French ...

Fate Therapeutics (FATE) presented initial clinical and translational data from the company’s Phase 1 study of FT522 in relapsed / refractory ...

Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting in San Diego. “These ...

Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens ...